E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Sickle Cell Disease with Vaso-Occlusive Crisis |
|
E.1.1.1 | Medical condition in easily understood language |
Sickle Cell Disease in hospitalized subjects Experiencing a Vaso-Occlusive Crisis |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10040644 |
E.1.2 | Term | Sickle cell disease |
E.1.2 | System Organ Class | 100000004850 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to demonstrate the efficacy of MST-188 in reducing the duration of vaso-occlusive crisis (VOC) in subjects with sickle cell disease (SCD). The duration of VOC will be measured from the time of randomization to the time at which a subject receives the last dose of parenteral opioid analgesia for the treatment of VOC prior to hospital discharge. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives are:
o To compare the re-hospitalization rate (for VOC) between the treatment arms.
o To compare the occurrence of acute chest syndrome (ACS) between the treatment arms. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
The sub-studies Pharmacodynamic laboratory biomarkers will be evaluated in a sub-study to this trial.
The effects of tissue oxygen saturation will be evaluated in a sub-study to this trial. These sub-studies will only be conducted in United States. |
|
E.3 | Principal inclusion criteria |
1. Age 4 through 65 years
2. Subject has a confirmed diagnosis of HbSS, HbSC, HbSβ+thal, or HbSβ0thal
3. Subject is experiencing acute pain typical of vaso-occlusive crisis requiring treatment with parenteral analgesia
4. Subject requires hospitalization |
|
E.4 | Principal exclusion criteria |
1. Subject has acute chest syndrome
2. Subject's laboratory results indicate inadequate organ function
3. Subject is pregnant or nursing an infant
4. Subject had a painful crisis requiring hospitalization within the preceding 14 days or has experienced > 5 hospitalizations for VOC in the prior 6 months
5. Subject has been transfused within the past 14 days
6. Subject is hospitalized for a condition other than VOC
7. Subject has complications related to SCD |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint of the study is the time from randomization to last parenteral opioid analgesic dose for the treatment of VOC prior to hospital discharge. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The time from randomization to last parenteral opioid analgesic dose for the treatment of VOC prior to hospital discharge. |
|
E.5.2 | Secondary end point(s) |
Secondary Endpoints
1. Re-hospitalization for VOC: The number and percent of subjects who are re-hospitalized for VOC within 14 days after discharge from the hospital.
2. Occurrence of ACS: The number and percent of subjects who meet the protocol definition of ACS within 120 hours of randomization. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. Within 14 days after discharge from the hospital.
2. Within 120 hours of randomization |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 4 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Belgium |
Brazil |
Dominican Republic |
Lebanon |
Netherlands |
Oman |
Panama |
Saudi Arabia |
Spain |
Turkey |
United Kingdom |
United States |
Jordan |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS: 30-day post-hospitalization contact: Last subject will be queried regarding re-hospitalization for VOC 30 days (±2 days) following discharge. If this date is within 2 days of the 30-Day Post-Infusion Follow-up visit, the visits may be combined. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 7 |
E.8.9.2 | In all countries concerned by the trial days | 0 |